Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Bio*One Launch Dx Assays JV in Singapore

NEW YORK (GenomeWeb News) – Nine months after saying that they would form a new molecular diagnostics joint venture, called Dx Assays, in Singapore, Qiagen and Bio*One Capital said today that the new venture has officially launched its operations.
The partners announced last December that they would launch the venture, which will focus on developing tests for infectious diseases and oncology applications. It expects to complete initial assay projects by the end of this year and to launch its first products over the next one to two years.
“By leveraging the development capabilities of Dx Assays, Qiagen can further strengthen its presence in the rapidly growing Asian market and expand its global portfolio of molecular testing solutions,” said Qiagen CEO Peer Schatz in a statement.
He noted that Asia is the firm’s fastest-growing market, and the company has seven offices in the region with more than 370 employees.
Earlier this year, Qiagen opened a new service solutions center in Singapore to serve the entire Asia-Pacific region. Qiagen said that the new center will help it serve customers in the research, applied testing, pharmaceutical, and molecular diagnostics markets in the entire Asia-Pacific region including Australia.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.